- Home
- BCG vs XGN Comparison
BCG vs XGN Comparison
Compare BCG & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- XGN
- Stock Information
- Founded
- BCG 2016
- XGN 2002
- Country
- BCG United States
- XGN United States
- Employees
- BCG N/A
- XGN N/A
- Industry
- BCG
- XGN Medical Specialities
- Sector
- BCG
- XGN Health Care
- Exchange
- BCG Nasdaq
- XGN Nasdaq
- Market Cap
- BCG 54.3M
- XGN 49.4M
- IPO Year
- BCG N/A
- XGN 2019
- Fundamental
- Price
- BCG $2.70
- XGN $2.65
- Analyst Decision
- BCG
- XGN Buy
- Analyst Count
- BCG 0
- XGN 1
- Target Price
- BCG N/A
- XGN $7.00
- AVG Volume (30 Days)
- BCG 10.8K
- XGN 24.1K
- Earning Date
- BCG 08-15-2024
- XGN 11-11-2024
- Dividend Yield
- BCG N/A
- XGN N/A
- EPS Growth
- BCG N/A
- XGN N/A
- EPS
- BCG N/A
- XGN N/A
- Revenue
- BCG $161,897,000.00
- XGN $56,660,000.00
- Revenue This Year
- BCG N/A
- XGN $9.98
- Revenue Next Year
- BCG N/A
- XGN $13.63
- P/E Ratio
- BCG N/A
- XGN N/A
- Revenue Growth
- BCG N/A
- XGN 7.05
- 52 Week Low
- BCG $2.50
- XGN $1.30
- 52 Week High
- BCG $16.61
- XGN $3.71
- Technical
- Relative Strength Index (RSI)
- BCG N/A
- XGN 39.30
- Support Level
- BCG N/A
- XGN $2.64
- Resistance Level
- BCG N/A
- XGN $3.03
- Average True Range (ATR)
- BCG 0.00
- XGN 0.17
- MACD
- BCG 0.00
- XGN -0.05
- Stochastic Oscillator
- BCG 0.00
- XGN 1.67
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.